Neurizon Therapeutics Limited has released a press release.
Appendix 4D & Half-Year Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Positive Phase 1 MEND Study Top-Line Results
- Presentation - Phase 1 Top-Line Results
- PharmAust Forms World-Class Scientific Advisory Board
- FDA Outlines Pathway to Accelerated Approval for MPL in MND
- Extension Study Begins, Analysis Suggests Survival Benefit
Later from Neurizon Therapeutics
- Positive clinical data filed with FDA to support ODD request
- Pause in Trading
- Media clarification
- Final Ethics Approval for Open-Label MND Extension Study
- Resignation of Dr Michael Thurn & appointment of John Clark
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics